Plotting a Startup Course in Turbulent Times -Michael Weickert, PhD-05/03/2011 - 8:30am

Event Information
Event Topic: 
Plotting a Startup Course in Turbulent Times
Event Date: 
05/03/2011 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Avenue, Sunnyvale, CA
Speaker Information
Event Speaker: 
Michael Weickert, PhD
Event Speaker Title: 
President and CEO
Event Speaker Company: 
S.E.A. Medical Systems
Event Speaker Bio: 

Dr. Weickert has been President and CEO of S.E.A. Medical Systems since 2008. Prior to S.E.A. Medical, he was Chief Business Officer at Corium International, Inc. an established transdermal drug delivery company, and StrataGent Life Sciences, Inc., a drug delivery startup, where he managed marketing, business development, finance and assisted the merger of the two companies. During more than 8 years at Nektar Therapeutics, a premier drug delivery company, Dr. Weickert held a variety of positions including Senior Program Executive and Senior Director Product Marketing, leading Portfolio Management and New Product Planning. He and his team evaluated hundreds of pharmaceutical and device product ideas and in-licensing opportunities and wrote over 30 business plans including one that became the spin-out Pearl Therapeutics. He collaborated with Business Development on partnering efforts in the US, EU, and Japan. In 2000, he created an anti-infectives business unit that placed four products in development and formed the core of the $115M pulmonary business acquisition by Novartis in 2008. At Ligand Pharmaceuticals, Somatogen, Inc., and Nektar, he led the development of small molecule, biologic and drug delivery products respectively.

As a private consultant with Wit Creek Partners, Dr. Weickert has prepared business and marketing plans for a Nobel Prize winner’s startup, several other Venture-backed startups, and profitable companies with groundbreaking therapies, and has led development of pharmaceutical and drug delivery products. Dr. Weickert is currently an advisor for several startups.

Dr. Weickert is also an investor in startup companies as a member of Life Science Angels, a limited partner with Quantum Technology Partners, and a venture partner with Kranenburg Fund.

Prior to joining industry, Dr. Weickert researched gene regulation at the National Cancer Institute of NIH. He received his Ph.D. and M.S. in Genetics from the University of Wisconsin.

Event Details
Event Details: 

The financial collapse of 2008 disrupted lives and businesses and upended the startup ecosystem. Conventional wisdom is that many startups that survived or began in that investment winter will be winners in future investor portfolios. This is the story of S.E.A. Medical Systems, incorporated in October of 2008, right as the financial world was plunging into chaos. By adjusting to circumstances and heeding feedback from investors, a course was plotted that has led to a much better situation than imagined at the outset. Non-regulated products, early corporate interest, and the discipline to only do good deals, has been key to keeping the decision-making in the hands of the founders and plotting a course to great innovations for medicine.